Hims & Hers Expands North American Footprint with Canadian Market Entry

The telehealth provider Hims & Hers officially launched operations in Canada on December 4, 2025. This strategic move was executed through the acquisition of Livewell, a domestic digital health platform. The expansion grants the company access to a substantial new market where approximately two-thirds of the adult population is classified as overweight or living with obesity. The timing is considered strategic, aligning with the anticipated 2026 approval of generic semaglutid in Canada.

Strategic Rationale and Financial Confidence

This Canadian foray follows a familiar playbook, mirroring the company’s earlier UK expansion via the takeover of Zava. By leveraging Livewell’s established local infrastructure, Hims & Hers can navigate regulatory frameworks efficiently and begin serving customers immediately. The geographic diversification also serves as a counterbalance to intensified competition within the United States. In February 2025, the U.S. Food and Drug Administration (FDA) officially declared an end to the semaglutid supply shortage, a development that increased pressure on the market for compounded GLP-1 medications.

Concurrently, demonstrating confidence in its financial position, the company’s management approved a new share repurchase program on November 17. This authorization, valued at $250 million, replaces a previous $100 million buyback plan. The move signals management’s belief in robust cash flows, even amid capital-intensive international expansion efforts.

Should investors sell immediately? Or is it worth buying Hims & Hers?

Market Response and Technical Outlook

Investor reaction to the news has been measured. After reaching an interim high of $39.12 on December 8, the share price retreated by approximately 15 percent. This pullback is attributed to profit-taking following a strong yearly gain of about 45 percent, coupled with broader sector rotation. Currently, the stock is consolidating above a key support level identified at $32.50.

As the company looks ahead to the first quarter of 2026, market participants are likely to focus on two critical metrics: subscriber growth within the new Canadian market and margin progression following the integration of Livewell. From a technical analysis perspective, a sustained breakout above the $35 price level would be viewed as the next bullish signal for the equity.